论文部分内容阅读
溶栓药物 为了增加局部溶栓作用,减少对全身的影响,溶栓药物发展包括以下3方面:①重组组织型纤溶酶原激活物(rt-PA)与单链尿激酶型纤溶酶原激活物(scu-PA)使用,通过共同作用或新的作用达到血栓完全溶解。②纤溶药物与抗纤维蛋白抗
Thrombolytic drugs in order to increase the role of local thrombolysis and reduce the impact on the body, thrombolytic drug development, including the following three aspects: ① recombinant tissue-type plasminogen activator (rt-PA) and single-chain urokinase-type plasminogen Activator (scu-PA) is used to achieve complete thrombolytic dissolution by either co-acting or new action. ② fibrinolytic drugs and anti-fibrin resistance